Teva, US Military complete first year shipments of Adenovirus vaccine

The vaccine is intended to protect the recruits undergoing basic training from respiratory sickness caused by adenovirus infections.

The US Army Medical Materiel Development Activity adenovirus vaccine product manager Clifford Snyder said, "Since the program began last year, combined data from the training installations indicates that the vaccine has reduced the incidence of febrile respiratory illness by over 75% and essentially eliminated the threat posed by adenovirus types 4 and 7."

Under the Adenovirus vaccine project that was restarted in October 2011, around 200,000 military training participants were vaccinated.

The USFDA approved the vaccine for Military Use Only in March 2011 to help cut costs, time and wages at the same time protect the health of the participants.

Teva Select Brands general manager and vice president Michael McHugh said, "We are proud of our partnership with the Military and we hope to continue supplying this important vaccine as long as it is needed by our Government."